Sivritepe, RıdvanUçak Basat, SemaBaygül, ArzuKüçük, Eyüp Veli2022-02-022022-02-022022Sivritepe, R., Uçak Basat, S., Baygül, A. ve Küçük, E. V. (2022). The effect of interleukin-6 level at the time of hospitalisation on erectile functions in hospitalised patients with COVID-19. Andrologia, 54(1). https://dx.doi.org/10.1111/and.142850303-45691439-0272https://dx.doi.org/10.1111/and.14285https://hdl.handle.net/20.500.12511/8948We evaluated the relationship between erectile dysfunction (ED) and IL-6 levels in males with COVID-19. The study included 80 male patients aged 30-45 years who were hospitalised due to COVID-19. The International Index of Erectile Function (IIEF-5) questionnaire was used to assess erectile function. The IIEF-5 questionnaire was re-administered at a 3-month control visit after discharge, and the change score from baseline was recorded. The patients were divided into three groups according to the IIEF-5 score at 3 months as Group 1 (severe ED), Group 2 (moderate ED) and Group 3 (no ED), and into two groups according to IL-6 level at the time of admission as Group A (IL-6 <= 50 ng/ml) and Group B (IL-6 > 50 ng/ml). The change in the IIEF-5 score (p < .001) was significantly greater in Group B than in Group A. There was also significant difference in IL-6 between Group 1 and Group 2 (p = .008). The correlation analysis revealed a moderate correlation between IL-6 level and the change in IIEF-5 score and D-dimer level (r:0.529, p < .001) and a weak correlation between IL-6 level and FSH (r:0.309, p = .005). The present study suggests that elevated IL-6 levels in male patients hospitalised due to COVID-19 might be related to the risk of developing ED.eninfo:eu-repo/semantics/embargoedAccessCOVID-19Erectile DysfunctionIIEF-5Interleukin-6Article54110.1111/and.14285Q3Q2